The EC Pharmaceutical Inquiry: Behind the Headlines, What is the Real Story on Innovation and Generic Competition in Pharmaceuticals?
Antitrust Chronicle, 2008, vol. 11
While the pharmaceutical sector waits for the European CommissionÃ¢â‚¬â„¢s interim report and hearing scheduled for November 28, 2008, there is an opportunity to step back and examine critically the premise of the inquiryÃ¢â‚¬â€ started infamously with dawn raids on January 16, 2008Ã¢â‚¬â€ that, as Commissioner Kroes announced, Ã¢â‚¬Å“if innovative products are not being produced, and cheaper generic alternatives Ã¢â‚¬Â¦ delayed, then we need to find out why and, if necessary, take action.Ã¢â‚¬Â
References: Add references at CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
http://www.competitionpolicyinternational.com/the- ... n-in-pharmaceuticals (application/pdf)
Requires login and subscription
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:cpi:atchrn:11.1.2008:i=5163
Access Statistics for this article
More articles in Antitrust Chronicle from Competition Policy International
Bibliographic data for series maintained by Lindsay McSweeney (). This e-mail address is bad, please contact .